- Home
- RILYP vs GALT Comparison
RILYP vs GALT Comparison
Compare RILYP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.14
Company Overview
Basic Information| Metric | RILYP | GALT |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | United States |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 176.7M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | RILYP | GALT |
|---|---|---|
| Price | $9.14 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 12.0K | ★ 281.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $854,383,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $1.15 |
| 52 Week High | $14.50 | $7.13 |
Technical Indicators
Market Signals| Indicator | RILYP | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 50.65 |
| Support Level | $8.70 | $2.88 |
| Resistance Level | $14.50 | $3.27 |
| Average True Range (ATR) | 0.73 | 0.24 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 18.39 | 44.27 |
Price Performance
Historical Comparison RILYP
GALT
About RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.